
Vimta Labs Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Vimta Labs aims to achieve Rs. 500 Crores revenue by FY2026, though it acknowledges this target will not be easy after a flat FY2024.
- The company is committed to driving growth, focusing on pharma (especially specialty and large molecules) and food segments.
- Growth in topline will be the key driver for improving margins towards 30-31% EBITDA.
- Electronics & Electrical (E&E) segment is expected to grow strongly, targeting Rs. 30 Crores revenue in the next 2-3 years, with potential to reach Rs. 50 Crores by FY2026-27.
- Capex is in progress to add capacity (e.g., new EMI EMC chamber) to support growth in E&E and life sciences.
- Demand in pharma is good with evolving development pipelines; food segment saw recovery but import volumes remain low.
- Regulatory approvals and capacity expansions are expected to support increased volumes.
- Large molecule business is developing steadily, with expansion into preclinical, clinical, and analytical services.
See what Vimta Labs management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Vimta Labs management said on order book — free account, 30 seconds.
Capex plans
Yes- Current FY2024 capex is on track, with about Rs.90 Crores planned primarily for project expansion and routine investments.
- New facility construction delayed by 6-7 weeks; expected to start moving in by mid-March 2024.
- Additional space created for one more EMI/EMC chamber, expected to be added within the next 6-8 months with a capex of Rs.4.5 to 5.5 Crores.
- No major new capex planned for the next 1.5 years except for the EMI/EMC chamber.
- Future capex decisions will depend on emerging opportunities requiring new capabilities and technology investments.
- Company committed to capacity building for life sciences (large molecules) and expanding analytical and preclinical capabilities.
- Strategic investments or ventures in contract manufacturing for large molecules are under open discussion at the Board level but no final decision yet.
Track Vimta Labs — get its next earnings analysis in your feed
How does Vimta Labs rank vs peers in Healthcare Services?
Pro featureHow does Vimta Labs rank in Healthcare Services?
Compare Vimta Labs against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Vimta Labs's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.